INVA Stock Summary and Trading Ideas (Innoviva | NASDAQ:INVA)

Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.

Innoviva trades on the NASDAQ stock market under the symbol INVA.

As of March 9, 2026, INVA stock price climbed to $22.32 with 551,049 million shares trading.

INVA has a beta of 0.02, meaning it tends to be less sensitive to market movements. INVA has a correlation of 0.00 to the broad based SPY ETF.

INVA has a market cap of $1.67 billion. This is considered a Small Cap stock.

Last quarter Innoviva reported $115 million in Revenue and $1.94 earnings per share. This beat revenue expectation by $12 million and exceeded earnings estimates by $1.55.

In the last 3 years, INVA traded as high as $25.15 and as low as $10.64.

The top ETF exchange traded funds that INVA belongs to (by Net Assets): IJR, VTI, AVUV, VB, IWM.

INVA has outperformed the market in the last year with a return of +26.9%, while the SPY ETF gained +19.7%. In the last 3 month period, INVA beat the market returning +7.6%, while SPY returned -0.8%. However, in the most recent 2 weeks INVA has underperformed the stock market by returning -4.6%, while SPY returned -1.6%.

INVA support price is $21.51 and resistance is $22.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INVA shares will trade within this expected range on the day.